PDCD1 and neoplasm: The most studied way is using antibodies to block the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway, an immune checkpoint that is exploited by tumor cells (Sacher and Gandhi, 2016).